RXRX - Recursion Pharmaceuticals, Inc. Stock Price, Fair Value and News

8.35USD+0.30 (+3.73%)Market Closed

Market Summary

USD8.35+0.30

Market Closed

3.73%

RXRX Alerts

3 major insider sales recently.

RXRX Stock Price

View Fullscreen

RXRX RSI Chart

RXRX Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-5.6

Price/Sales (Trailing)

42.89

EV/EBITDA

-5.55

Price/Free Cashflow

-6.01

RXRX Price/Sales (Trailing)

RXRX Profitability

EBT Margin

-718.35%

Return on Equity

-88.27%

Return on Assets

-63.48%

Free Cashflow Yield

-16.65%

RXRX Fundamentals

RXRX Revenue

Revenue (TTM)

46.2M

Rev. Growth (Yr)

13.68%

Rev. Growth (Qtr)

26.66%

RXRX Earnings

Earnings (TTM)

-354.1M

Earnings Growth (Yr)

-39.87%

Earnings Growth (Qtr)

1.75%

Breaking Down RXRX Revenue

Last 7 days

9.7%

Last 30 days

-4.7%

Last 90 days

2.8%

Trailing 12 Months

-35.3%

How does RXRX drawdown profile look like?

RXRX Financial Health

Current Ratio

4.65

RXRX Investor Care

Shares Dilution (1Y)

23.95%

Diluted EPS (TTM)

-1.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	46.2M	0	0	0
2023	46.6M	50.0M	47.4M	44.6M
2022	12.9M	18.1M	28.7M	39.8M
2021	25.2M	8.8M	10.3M	10.2M
2020	2.7M	3.1M	3.6M	4.0M
2019	0	0	0	2.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO	Dr. Christopher C. Gibson Ph.D.
WEBSITE	recursion.com
INDUSTRY	Biotechnology
EMPLOYEES	550

Recursion Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Recursion Pharmaceuticals, Inc.? What does RXRX stand for in stocks?

RXRX is the stock ticker symbol of Recursion Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Recursion Pharmaceuticals, Inc. (RXRX)?

As of Fri Jul 26 2024, market cap of Recursion Pharmaceuticals, Inc. is 1.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RXRX stock?

You can check RXRX's fair value in chart for subscribers.

Is Recursion Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether RXRX is over valued or under valued. Whether Recursion Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Recursion Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RXRX.

What is Recursion Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, RXRX's PE ratio (Price to Earnings) is -5.6 and Price to Sales (PS) ratio is 42.89. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RXRX PE ratio will change depending on the future growth rate expectations of investors.